Protocol Ledger

NCT03182907 · Phase III · COMPLETED

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

Interventional Phase III clinical trial protocol NCT03182907 sponsored by Merck & Co. in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-03-27 Enrollment: 148 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03182907
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)148 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03182907
Protocol FieldVerified Registry Value
NCT IdentifierNCT03182907
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment148 participants (ACTUAL)
Registered Start Date2018-03-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI